Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 2/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 9/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403161 | 0.79 | HRH1 (0.86) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL11329969 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL2836377 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL1204774 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL2849801 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL5089222 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL29060377 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL11328616 | 0.77 | HRH1 (0.83) | HRH1HTR2ASLC7A5MAOATAAR1 | |
| SCHEMBL17280848 | 0.77 | HRH1 (0.43) | HRH1HTR2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7373079 | 0.75 | HRH1 (0.59) | HRH1HTR2ASLC7A5MAOATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2243805-B1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | NIPPON KAYAKU KK (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-7985287-B2 | Anthrapyridone compound or a salt thereof, magenta ink composition containing the anthrapyridone compound and colored product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2011-07-26 | — | — | US | disclosed |
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2243805-A1 | ANTHRAPYRIDONE COMPOUND OR SALT THEREOF, MAGENTA INK COMPOSITION CONTAINING THE ANTHRAPYRIDONE COMPOUND, AND COLORED BODY | Nippon Kayaku Kabushiki Kaisha (JP) | 2010-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291360-A1 | Anthrapyridone Compound Or A Salt Thereof, Magenta Ink Composition Containing The Anthrapyridone Compound and Colored Product | MLLT3, MLLT1, H1-3 | HRH1 571/4885HTR2A 3427/4885CYP1A2 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.